P
Pierre Authié
Researcher at Pasteur Institute
Publications - 13
Citations - 149
Pierre Authié is an academic researcher from Pasteur Institute. The author has contributed to research in topics: Biology & Viral vector. The author has an hindex of 3, co-authored 6 publications receiving 29 citations.
Papers
More filters
Journal ArticleDOI
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
Min Wen Ku,Maryline Bourgine,Pierre Authié,Jodie Lopez,Kirill Nemirov,Fanny Moncoq,Amandine Noirat,Benjamin Vesin,Fabien Nevo,Catherine Blanc,Philippe Souque,Houda Tabbal,Emeline Simon,David Hardy,Marine Le Dudal,Françoise Guinet,Laurence Fiette,Hugo Mouquet,François Anna,Annette Martin,Nicolas Escriou,Laleh Majlessi,Pierre Charneau +22 more
TL;DR: These results provide evidence of marked prophylactic effects of the LV-based vaccination against SARS-CoV-2 and designate intranasal immunization as a powerful approach against COVID-19.
Journal ArticleDOI
Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.
Min-Wen Ku,Pierre Authié,Maryline Bourgine,François Anna,Amandine Noirat,Fanny Moncoq,Benjamin Vesin,Fabien Nevo,Jodie Lopez,Philippe Souque,Catherine Blanc,Ingrid Fert,Sébastien Chardenoux,llta Lafosse,Delphine Cussigh,David Hardy,Kirill Nemirov,Françoise Guinet,Francina Langa Vives,Laleh Majlessi,Pierre Charneau +20 more
TL;DR: In this paper, a transgenic mouse strain expressing the human angiotensin-converting enzyme 2 was generated, and the brain permissiveness to SARS-CoV-2 replication was shown to be high in the lung.
Journal ArticleDOI
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa
Benjamin Vesin,Jodie Lopez,Amandine Noirat,Pierre Authié,Ingrid Fert,Fabien Le Chevalier,Fanny Moncoq,Kirill Nemirov,Catherine Blanc,Cyril Planchais,Hugo Mouquet,François Gouin,David Hardy,Francina Langa Vives,Christiane Gerke,François Anna,Maryline Bourgine,Laleh Majlessi,Pierre Charneau +18 more
TL;DR: In this article , an optimized cross-protective intranasal booster against COVID-19 was proposed using the lentiviral vaccination vector (LV), which is particularly suitable for this route of immunization owing to its non-cytopathic, non-replicative and scarcely inflammatory properties.
Journal ArticleDOI
Lentiviral vector induces high-quality memory T cells via dendritic cells transduction
Min Wen Ku,Pierre Authié,Fabien Nevo,Philippe Souque,Maryline Bourgine,Marta Romano,Pierre Charneau,Laleh Majlessi +7 more
TL;DR: In this paper, a lentiviral vector harboring the human β2-microglobulin promoter, with predominant expression in immune cells and minimal proximal enhancers to improve vector safety, was reported to efficiently transduces major dendritic cell subsets in vivo.
Posted ContentDOI
Intranasal Vaccination with a Lentiviral Vector Strongly Protects against SARS-CoV-2 in Mouse and Golden Hamster Preclinical Models
Min-Wen Ku,Maryline Bourgine,Pierre Authié,Jodie Lopez,Kirill Nemirov,Fanny Moncoq,Amandine Noirat,Benjamin Vesin,Fabien Nevo,Catherine Blanc,Philippe Souque,Tabbal H,Simon E,Le Dudal M,Françoise Guinet,Laurence Fiette,Hugo Mouquet,François Anna,Annette Martin,Nicolas Escriou,Laleh Majlessi,Pierre Charneau +21 more
TL;DR: The results provide evidence of marked prophylactic effects of the LV-based vaccination against SARS-CoV-2 and designate the intranasal immunization as a powerful approach against COVID-19.